COVID-19 continues to put a strain on the world's healthcare system.

In the

past, observational analysis of the United States multicenter registry showed that those with

STEMI (ST-elevation due to myocardial infarction) (STEMI) and COVID-19 had higher

mortality, complicated presentation, and did not have the propensity to undergo primary

percutaneous coronary intervention (PPCI) when compared to historically matched controls.

There is adequate proof in support of minimizing the door-to-balloon period to alleviate the

outcomes in STEMI, but there are several factors that may delay the activation, transfers of

cardiac catheterization as well as clarification in a can in equivocal cases

The PRECISION GRX trial investigated a second-generation teleoperated PCI

framework. This trial's findings were incredibly positive, and more investigation will almost

certainly be carried out to aid in minimizing exposure to radiation reduce radiation and

orthopedic grievances among percutaneous coronary cardiologists. Patients' understanding of the

reason for their PCI, when it was conducted, as well as the type and size of catheter used, may

affect the quality of their successive medical care, particularly if it is supplied by a new

physician.

The previous year was an exciting moment in diagnostic lipidology since we have

discovered more about available treatments as well as treatments designed to target novel

channels found through genetic research. The prime focus remained LDL cholesterol, and many

drugs with different methods for lowering LDL cholesterol were investigated. New evidence on

the deplorable state of triglyceride-rich lipoproteins has reignited interest in developing drug

therapies to lower them. Since last year's European Heart Journal report, there has been

significant progress in all aspects of cardiology. Notably, endovascular cardiology was practiced

during wave after wave of the COVID-19 pandemic, which continues to be a significant burden
for all healthcare care providers worldwide. In our yearly review, we will revisit advancements

in coronary percutaneous intervention (PCI), structural heart interventions, and adjunctive

pharmacotherapy.

The increasing burden of valvular heart disease (VHD) is recognized by experts,

especially in an older population, but the wider populace and key parties are less cognizant of

these circumstances. This, in addition to new non-surgical interventional treatment options, has

led to an increase in interest in researchers in VHD, with an unparalleled number of studies

published in the last year. The majority of these publications are about endovascular treatment,

such as technological advances and outcomes versus surgical procedures or therapeutic

treatment.